BRPI0412352A - processo para a preparação de derivados de tetrazol de azidas de organo boro e organo alumìnio - Google Patents
processo para a preparação de derivados de tetrazol de azidas de organo boro e organo alumìnioInfo
- Publication number
- BRPI0412352A BRPI0412352A BRPI0412352-2A BRPI0412352A BRPI0412352A BR PI0412352 A BRPI0412352 A BR PI0412352A BR PI0412352 A BRPI0412352 A BR PI0412352A BR PI0412352 A BRPI0412352 A BR PI0412352A
- Authority
- BR
- Brazil
- Prior art keywords
- organo
- preparation
- azides
- aluminum
- boron
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000003536 tetrazoles Chemical class 0.000 title abstract 3
- -1 organo aluminum azides Chemical class 0.000 title abstract 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title 1
- 229910052796 boron Inorganic materials 0.000 title 1
- 125000000962 organic group Chemical group 0.000 title 1
- 210000000056 organ Anatomy 0.000 abstract 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
"PROCESSO PARA A PREPARAçãO DE DERIVADOS DE TETRAZOL DE AZIDAS DE ORGANO BORO E ORGANO ALUMìNIO". A presente invenção diz respeito a um método para preparar tetrazóis substituídos, compostos obtidos de acordo com este método, reagentes novos e derivados de tetrazol novos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49134003P | 2003-07-30 | 2003-07-30 | |
US49111803P | 2003-07-30 | 2003-07-30 | |
US49111603P | 2003-07-30 | 2003-07-30 | |
PCT/US2004/024657 WO2005011656A2 (en) | 2003-07-30 | 2004-07-29 | Pyridyl derivatives and their use as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412352A true BRPI0412352A (pt) | 2006-09-05 |
Family
ID=34119804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412352-2A BRPI0412352A (pt) | 2003-07-30 | 2004-07-29 | processo para a preparação de derivados de tetrazol de azidas de organo boro e organo alumìnio |
Country Status (15)
Country | Link |
---|---|
US (2) | US7605161B2 (pt) |
EP (2) | EP1651606B1 (pt) |
JP (1) | JP4782008B2 (pt) |
KR (1) | KR20060036106A (pt) |
AU (2) | AU2004261267B9 (pt) |
BR (1) | BRPI0412352A (pt) |
CA (1) | CA2533900A1 (pt) |
EC (1) | ECSP066312A (pt) |
ES (1) | ES2397389T3 (pt) |
IL (1) | IL173398A0 (pt) |
MA (1) | MA28008A1 (pt) |
NO (1) | NO20060972L (pt) |
SG (1) | SG145700A1 (pt) |
TN (1) | TNSN06036A1 (pt) |
WO (1) | WO2005011656A2 (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
AU2004261250B2 (en) * | 2003-07-29 | 2009-02-26 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
US20070249620A1 (en) * | 2004-07-02 | 2007-10-25 | Hitoshi Kurata | Urea Derivative |
JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
EP1804799B1 (en) | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体 |
MX2007003332A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
MX2007003327A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
DE602005025924D1 (en) * | 2004-09-20 | 2011-02-24 | Xenon Pharmaceuticals Inc | Royl-coa-desaturase |
ES2682282T3 (es) | 2004-10-29 | 2018-09-19 | Kalypsys, Inc. | Compuestos bicíclicos sustituidos con sulfonilo como moduladores de PPAR |
CN101068786A (zh) * | 2004-12-03 | 2007-11-07 | 霍夫曼-拉罗奇有限公司 | 作为h3拮抗剂的3-取代的吡啶衍生物 |
WO2006125179A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Tricyclic compounds and their uses as therapeutic agents |
WO2006125180A1 (en) * | 2005-05-19 | 2006-11-23 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their uses as therapeutic agents |
WO2007044085A2 (en) * | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
MX2007015216A (es) | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
NZ566831A (en) | 2005-10-25 | 2011-09-30 | Kalypsys Inc | Salts of modulators of PPAR and methods of treating metabolic disorders |
US7799787B2 (en) | 2005-12-20 | 2010-09-21 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
PE20071232A1 (es) | 2006-02-07 | 2008-02-18 | Wyeth Corp | Derivados de piperidina o piperazina como inhibidores de 11-beta hsd1 |
WO2007136746A2 (en) * | 2006-05-19 | 2007-11-29 | Xenon Pharmaceuticals Inc. | Macrocyclic compounds and their uses as stearoyl-coa desaturase |
ATE486862T1 (de) | 2006-06-05 | 2010-11-15 | Novartis Ag | Organische verbindungen |
BRPI0719122A2 (pt) | 2006-08-24 | 2013-12-10 | Novartis Ag | Compostos orgânicos |
EP2099755A2 (en) * | 2006-11-20 | 2009-09-16 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
PL2142529T3 (pl) * | 2007-04-27 | 2014-06-30 | Purdue Pharma Lp | Antagoniści trpv1 i ich zastosowania |
US7842696B2 (en) | 2007-06-21 | 2010-11-30 | Forest Laboratories Holdings Limited | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase |
DE602008003586D1 (de) | 2007-08-08 | 2010-12-30 | Graceway Pharmaceuticals Llc | Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus |
WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
BRPI0913986A2 (pt) | 2008-03-26 | 2015-10-20 | Daiichi Sankyo Co Ltd | composto, composição farmacêutica, e, uso de um composto |
WO2010028761A1 (de) * | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
WO2010075356A1 (en) * | 2008-12-23 | 2010-07-01 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
AU2010215035B2 (en) | 2009-02-17 | 2014-06-12 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
JP2012522748A (ja) * | 2009-04-01 | 2012-09-27 | ノバルティス アーゲー | ステアロイル−coaデサチュラーゼ調節用スピロ誘導体 |
GB0907425D0 (en) * | 2009-04-29 | 2009-06-10 | Glaxo Group Ltd | Compounds |
EP2459568A4 (en) | 2009-07-28 | 2013-02-27 | Merck Frosst Canada Ltd | NOVEL SPIRO COMPOUNDS USEFUL AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS |
EP2475367A1 (en) | 2009-09-10 | 2012-07-18 | Centre National De La Recherche Scientifique | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
MY185061A (en) | 2011-06-22 | 2021-04-30 | Shionogi & Co | Trpv1 antagonists including dihydroxy substituent and uses thereof |
BR112014029365A2 (pt) | 2012-05-22 | 2017-06-27 | Hoffmann La Roche | inibidores seletivos de células indiferenciadas |
JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス,インコーポレーテッド | 化合物及びその使用 |
KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
HUE049979T2 (hu) | 2017-03-20 | 2020-11-30 | Forma Therapeutics Inc | Pirrolopirrol készítmények piruvát-kináz (PKR) aktivátorokként |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
BR112021005188A2 (pt) | 2018-09-19 | 2021-06-08 | Forma Therapeutics, Inc. | tratamento de anemia falciforme com um composto de ativação de piruvato cinase r |
CN113226356A (zh) | 2018-09-19 | 2021-08-06 | 福马治疗股份有限公司 | 活化丙酮酸激酶r |
CN113316571A (zh) * | 2018-11-14 | 2021-08-27 | 阿林齐生物制药公司 | 用于治疗白细胞介素1β相关病症的吡啶磺酰胺化合物 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007527A1 (en) | 1987-04-03 | 1988-10-06 | The Upjohn Company | Amino-9,10-secosteroids |
CA1338012C (en) * | 1987-04-27 | 1996-01-30 | John Michael Mccall | Pharmaceutically active amines |
US4994456A (en) * | 1989-03-01 | 1991-02-19 | Nisshin Flour Milling Co., Ltd. | Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same |
JP2502824B2 (ja) | 1991-03-13 | 1996-05-29 | 松下電器産業株式会社 | 平面型誘電体フィルタ |
JP2503198Y2 (ja) | 1991-06-17 | 1996-06-26 | 株式会社椿本チエイン | 搬送方向に傾動可能なワ―ク回動ア―ムを具えたワ―ク搬送装置 |
WO2000055120A1 (en) * | 1999-03-17 | 2000-09-21 | Astrazeneca Ab | Amide derivatives |
EP1180514A4 (en) * | 1999-04-09 | 2003-02-26 | Meiji Seika Kaisha | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMID DERIVATIVES, AND THEIR MEDICINAL PRODUCTS |
WO2001043746A1 (fr) * | 1999-12-14 | 2001-06-21 | Nippon Shinyaku Co., Ltd. | Composition medicinale |
DE60142692D1 (de) | 2000-02-24 | 2010-09-09 | Xenon Genetics Inc | Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika |
BR0109188A (pt) * | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
ATE402262T1 (de) | 2000-09-26 | 2008-08-15 | Xenon Pharmaceuticals Inc | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden |
US20020169166A1 (en) * | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
FR2823209B1 (fr) | 2001-04-04 | 2003-12-12 | Fournier Lab Sa | Nouvelles thiohydantoines et leur utilisation en therapeutique |
WO2002102778A1 (fr) * | 2001-06-15 | 2002-12-27 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de phenylpyridinecarbonylpiperazine |
JPWO2003037862A1 (ja) * | 2001-10-30 | 2005-02-17 | 日本新薬株式会社 | アミド誘導体及び医薬 |
JP2005510564A (ja) * | 2001-11-28 | 2005-04-21 | 藤沢薬品工業株式会社 | アポリポタンパク質b阻害剤としての複素環式アミド化合物 |
AU2003203148A1 (en) | 2002-02-05 | 2003-09-02 | High Point Pharmaceuticals, Llc | Novel aryl- and heteroarylpiperazines |
US20030195192A1 (en) * | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
PL214279B1 (pl) | 2002-03-13 | 2013-07-31 | Janssen Pharmaceutica Nv | Pochodna sulfonyloaminowa, sposób jej wytwarzania i zastosowanie oraz kompozycja farmaceutyczna i sposób jej wytwarzania |
US7501417B2 (en) | 2002-03-13 | 2009-03-10 | Janssen Pharmaceutica, N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
JP2005537228A (ja) * | 2002-04-25 | 2005-12-08 | ファルマシア・コーポレーション | ピペリジニル−及びピペラジニル−スルホニルメチルヒドロキサム酸並びにプロテアーゼ阻害剤としてのその使用 |
AU2003301436A1 (en) * | 2002-10-17 | 2004-05-04 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
JP2004203871A (ja) * | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
AU2004261250B2 (en) * | 2003-07-29 | 2009-02-26 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
RU2006105717A (ru) * | 2003-07-30 | 2007-09-20 | Зинон Фармасьютиклз Инк. (Ca) | Производные пиперазина и их применение в качестве терапевтических агентов |
-
2004
- 2004-07-29 EP EP04779655A patent/EP1651606B1/en not_active Expired - Lifetime
- 2004-07-29 EP EP10184703A patent/EP2316825A1/en not_active Withdrawn
- 2004-07-29 AU AU2004261267A patent/AU2004261267B9/en not_active Ceased
- 2004-07-29 JP JP2006522095A patent/JP4782008B2/ja not_active Expired - Fee Related
- 2004-07-29 WO PCT/US2004/024657 patent/WO2005011656A2/en active Application Filing
- 2004-07-29 SG SG200805679-8A patent/SG145700A1/en unknown
- 2004-07-29 CA CA002533900A patent/CA2533900A1/en not_active Abandoned
- 2004-07-29 ES ES04779655T patent/ES2397389T3/es not_active Expired - Lifetime
- 2004-07-29 BR BRPI0412352-2A patent/BRPI0412352A/pt not_active IP Right Cessation
- 2004-07-29 KR KR1020067002002A patent/KR20060036106A/ko not_active Application Discontinuation
- 2004-07-29 US US10/566,193 patent/US7605161B2/en not_active Expired - Fee Related
-
2006
- 2006-01-25 EC EC2006006312A patent/ECSP066312A/es unknown
- 2006-01-26 IL IL173398A patent/IL173398A0/en unknown
- 2006-01-27 TN TNP2006000036A patent/TNSN06036A1/en unknown
- 2006-02-27 MA MA28836A patent/MA28008A1/fr unknown
- 2006-02-28 NO NO20060972A patent/NO20060972L/no not_active Application Discontinuation
-
2009
- 2009-05-11 AU AU2009201861A patent/AU2009201861A1/en not_active Abandoned
- 2009-09-02 US US12/552,868 patent/US8153636B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2009201861A1 (en) | 2009-06-04 |
AU2009201861A8 (en) | 2009-06-11 |
EP1651606B1 (en) | 2012-10-24 |
KR20060036106A (ko) | 2006-04-27 |
EP1651606A2 (en) | 2006-05-03 |
CA2533900A1 (en) | 2005-02-10 |
US7605161B2 (en) | 2009-10-20 |
ES2397389T3 (es) | 2013-03-06 |
US20060199802A1 (en) | 2006-09-07 |
AU2004261267B9 (en) | 2009-04-09 |
EP2316825A1 (en) | 2011-05-04 |
AU2004261267A1 (en) | 2005-02-10 |
WO2005011656A3 (en) | 2005-05-06 |
IL173398A0 (en) | 2006-06-11 |
ECSP066312A (es) | 2006-07-28 |
NO20060972L (no) | 2006-05-02 |
SG145700A1 (en) | 2008-09-29 |
MA28008A1 (fr) | 2006-07-03 |
JP4782008B2 (ja) | 2011-09-28 |
TNSN06036A1 (en) | 2007-10-03 |
AU2004261267B2 (en) | 2009-02-12 |
WO2005011656A2 (en) | 2005-02-10 |
US20100048584A1 (en) | 2010-02-25 |
US8153636B2 (en) | 2012-04-10 |
JP2007500719A (ja) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412352A (pt) | processo para a preparação de derivados de tetrazol de azidas de organo boro e organo alumìnio | |
BRPI0412558A (pt) | processo para a preparação de derivados de tetrazol de azidas de organoboro e organoalumìnio | |
WO2006029193A3 (en) | Process for preparing substituted tetrazoles from aminotetrazole | |
BRPI0519496A2 (pt) | processo para preparar um composto ou uma composiÇço, e, composiÇço | |
BRPI0516911A (pt) | método para a preparação de um composto e composto de anilina | |
BRPI0409969A (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
BRPI0408492A (pt) | processo para preparar ditioésteres | |
BRPI0712101B8 (pt) | ácido beta-fenil-alfa-hidróxi propanóico substituído, método de síntese e uso do mesmo | |
BRPI0517455A (pt) | compostos orgánicos | |
BRPI0507979A (pt) | processo para preparação de um composto | |
CY1114362T1 (el) | Προσθετες ουσιες αλλοιωσης του ρυθμου σκληρυνσης του χημικου συνδυασμου πυριτικης και φωσφορικης κονιας και της σχετικης μεθοδου | |
BRPI0410635A (pt) | isÈmeros enriquecidos e opticamente puros de ligantes de quelação e agentes de contraste | |
MX2007007446A (es) | Procesos para la produccion de 4-aminoquinazolinas. | |
BR0317146A (pt) | Derivado de hemissulfato de azido citosina cristalino anidro | |
BRPI0409471B8 (pt) | processo para preparação de 2-cianopirrolidinas n-substituídas | |
BR0210278A (pt) | Processo para a preparação de l-ribavirina | |
BRPI0720835A2 (pt) | processo para preparação de 3,5-di-omicron-acil-2-fluoro-2-c-metil-d-ribono-gama-lactona | |
BRPI0411652A (pt) | processo para a preparação de derivados de espirobenzoazepina substituìdos não-peptìdicos | |
BRPI0409235A (pt) | processo para a produção de sal de amÈnio do ácido 2-hidróxi-4-metiltiobutìrico | |
BR0009453A (pt) | Processo para a preparação de um composto | |
BR0205172A (pt) | Processo para a sìntese de esfingosina | |
BR0315508A (pt) | Processo para preparação de compostos de pirazol | |
BR0113944A (pt) | Processo para a produção de compostos quirais | |
BRPI0416377A (pt) | processo para a sìntese de imidazóis | |
BR0115809A (pt) | Processo de ciclização para sìntese de compostos derivados de pirolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |